Tango Therapeutics
TNGX
120 hedge funds and large institutions have $846M invested in Tango Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 25 closing their positions.
144% more call options, than puts
Call options by funds: $22K | Put options by funds: $9K
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
8% more capital invested
Capital invested by funds: $781M → $846M (+$64.8M)
0.09% more ownership
Funds ownership: 92.2% → 92.29% (+0.09%)
5% less funds holding
Funds holding: 126 → 120 (-6)
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.92M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.45M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$3.36M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.69M |
| 5 |
AG
Artal Group
Luxembourg
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.02M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.32M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.81M |
| 4 |
Two Sigma Investments
New York
|
-$1.67M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.56M |
TNGX Hedge Fund Activity: Q2 2024 in Review
120 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q2 2024, worth a combined $846M — up 8.3% from $781M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TNGX and 20 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 39 added.
The largest buyer was Citadel Advisors, adding an estimated $5.92M. The largest seller was State Street, cutting an estimated $8.02M.
- 120 institutional investors held Tango Therapeutics (TNGX) as of Q2 2024, down from 126 in Q1 2024.
- Funds reported $846M of Tango Therapeutics stock for Q2 2024, up 8.3% quarter-over-quarter.
- 20 funds opened new Tango Therapeutics positions in Q2 2024 and 25 closed out, a net change of -5 holders.
- The largest Tango Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $5.92M added.
- The largest Tango Therapeutics seller in Q2 2024 was State Street, an estimated $8.02M sold.
Based on aggregated 13F filings for Q2 2024.